In June 2010 the drug company Novo Nordisk announced that its only conventional human biphasic insulin, human Mixtard 30, would no longer be available in the UK from January 2011, a decision that affects an estimated 90,000 patients Drug and Theraputics Bulletin (DTB), one of the BMJ’s sister journals, is campaigning against that decision. DTB editor Ike Ihenacho talks about the campaign.
Mabel Chew talks to the authors of a rational testing article on what to do about mildly abnormal serum amine transferase levels, what to suspect, and how to diagnose.
Finally, we have a musical interlude.